Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.

ABSTRACT: Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatostatin analogues, resulting in strongly increased progression-free survival and quality of life. There is nevertheless still room for improvement, as very few patients can be cured at this stage of disease. We aimed to specifically sensitize replicating tumor cells without further damage to healthy tissues. Thereto we investigated the DNA damaging effects of PRRT with the purpose to enhance these effects through modulation of the DNA damage response. Although PRRT induces DNA double strand breaks

SUBMITTER: Nonnekens J 

PROVIDER: S-EPMC4997239 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature